Ten months after devastating failure, Roche says it sees path forward for Huntington’s drug
If you had to pick 2021’s biggest drug development disappointment, it’d be hard to overlook the Roche-Ionis Huntington’s disease trial.
The Phase III study represented the community’s first major hope of having a treatment for the underlying cause of a devastating disease that steals most patients’ cognition in mid-life. Then, in March, Roche had to cut the trial short because the drug seemed to somehow be making patients worse.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.